First Ascent Biomedical
First Ascent Biomedical creates personalized cancer treatment plans by testing a patient’s tumor cells and using AI to predict effective therapies. Its Drug Prediction Platform (DxPP) combines functional drug testing that enriches chemo‑resistant and bulk tumor cells with DNA and RNA sequencing, bioinformatics, and causal machine learning to generate cellular response datasets. The company operates as a biotech B2B SaaS and services provider, delivering clinician‑ready reports for oncologists and advanced cancer patients via cloud infrastructure. DxPP evaluates hundreds of FDA‑approved drugs to recommend individualized combination therapies and is supported by validation studies with major cancer centers.
First Ascent Biomedical
First Ascent Biomedical creates personalized cancer treatment plans by testing a patient’s tumor cells and using AI to predict effective therapies. Its Drug Prediction Platform (DxPP) combines functional drug testing that enriches chemo‑resistant and bulk tumor cells with DNA and RNA sequencing, bioinformatics, and causal machine learning to generate cellular response datasets. The company operates as a biotech B2B SaaS and services provider, delivering clinician‑ready reports for oncologists and advanced cancer patients via cloud infrastructure. DxPP evaluates hundreds of FDA‑approved drugs to recommend individualized combination therapies and is supported by validation studies with major cancer centers.